Review article: Mild to moderate Crohn's disease - defining the basis for a new treatment algorithm

被引:52
作者
Sandborn, WJ
Feagan, BG
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Univ Western Ontario, Robarts Res Inst, London, ON, Canada
关键词
D O I
10.1046/j.1365-2036.2003.01661.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Previously, clinicians have had few choices in treating mild to moderate Crohn's disease. They currently treat these Crohn's disease patients with oral mesalamine and antibiotics. This treatment approach is based on the safety of these agents, and the perception that they are effective. This perception regarding efficacy may be influenced by publication bias. This review examines the efficacy and safety data of the conventional corticosteroids, mesalamine, sulfasalazine, budesonide and antibiotics for inducing the remission of mild to moderate Crohn's disease from randomized controlled trials, and proposes an evidence-based treatment approach. Sulfasalazine has demonstrated modest efficacy when Crohn's disease is confined to the colon. Mesalamine has no clear benefit over placebo in treating active Crohn's disease. Conventional corticosteroids effectively induce remission but are associated with unwanted adverse effects. Budesonide has similar efficacy to conventional steroids with far fewer adverse effects. Antibiotics have not consistently demonstrated efficacy. We propose a new evidence-based approach which suggests inducing remission of mild to moderate Crohn's disease with budesonide 9 mg/day for patients with ileal and/or right colonic involvement; sulfasalazine for those with disease limited to the colon; and conventional steroids for high disease activity, those who failed budesonide and those with left-sided disease who are allergic or intolerant to sulfasalazine.
引用
收藏
页码:263 / 277
页数:15
相关论文
共 70 条
[1]  
ALLAN R, 1977, GUT, V18, pA422
[2]   ANTIBIOTIC-THERAPY FOR TREATMENT IN RELAPSE OF INTESTINAL CROHNS-DISEASE - A PROSPECTIVE RANDOMIZED STUDY [J].
AMBROSE, NS ;
ALLAN, RN ;
KEIGHLEY, MRB ;
BURDON, DW ;
YOUNGS, D ;
BARNES, P ;
LENNARDJONES, JE .
DISEASES OF THE COLON & RECTUM, 1985, 28 (02) :81-85
[3]  
[Anonymous], CANADIAN J GASTROENT
[4]  
[Anonymous], 1990, CAN J GASTROENTEROL, DOI DOI 10.1155/1990/659079
[5]  
ANTHONISEN P, 1974, SCAND J GASTROENTERO, V9, P549
[6]   Preliminary study of ciprofloxacin in active Crohn's disease [J].
Arnold, GL ;
Beaves, MR ;
Pryjdun, VO ;
Mook, WJ .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (01) :10-15
[7]  
AZADKHAN AK, 1977, LANCET, V2, P892
[8]   Budesonide versus prednisone in the treatment of active Crohn's disease [J].
Bar-Meir, S ;
Chowers, Y ;
Lavy, A ;
Abramovitch, D ;
Sternberg, A ;
Leichtmann, G ;
Reshef, R ;
Odes, S ;
Moshkovitz, M ;
Bruck, R ;
Eliakim, R ;
Maoz, E ;
Mittmann, U .
GASTROENTEROLOGY, 1998, 115 (04) :835-840
[9]   CHRONIC INTERMITTENT ELEMENTAL DIET IMPROVES GROWTH FAILURE IN CHILDREN WITH CROHNS-DISEASE [J].
BELLI, DC ;
SEIDMAN, E ;
BOUTHILLIER, L ;
WEBER, AM ;
ROY, CC ;
PLETINCX, M ;
BEAULIEU, M ;
MORIN, CL .
GASTROENTEROLOGY, 1988, 94 (03) :603-610
[10]  
Bitton A, 1996, AM J GASTROENTEROL, V91, P1039